The Effect of Combination Chemotherapy with Vinorelbine, Carboplatin, and Ifosfamide in Patients with Advanced Non-Small Cell Lung Cancer.
- Author:
Young Woo LEE
1
;
Baek Yeol RYOO
;
Tae You KIM
;
Bong Seog KIM
;
Yeon Hee PARK
;
Hyun Ju HONG
;
Jin Young KWAG
;
Sang Won LEE
;
Yoon Koo KANG
Author Information
1. Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
NCI (vinorelbine, carboplatin, ifosfamide) combination chemotherapy
- MeSH:
Carboplatin*;
Carcinoma, Non-Small-Cell Lung*;
Disease-Free Survival;
Drug Therapy;
Drug Therapy, Combination*;
Humans;
Ifosfamide*;
Leukopenia;
Mesna;
Mortality;
Phlebitis;
Stomatitis;
Treatment Outcome
- From:Journal of the Korean Cancer Association
1999;31(6):1227-1235
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Despite recent advances in chemotherapy, the treatment outcome of advanced non-small cell lung cancer (NSCLC) remains poor and NSCLC is still the predominant source of cancer-related mortality in worldwide. Thus, we evaluated the efficacy and safety of a combination chemotherapy with vinorelbine, carboplatin, and ifosfamide (NCI) in advanced NSCLC patients. MATERIALS AND METHODS: A total of 26 patients was enrolled in this study between December 1997 and June 1998. All entered patients were treated with NCI combination chemotherapy (vinorelbine 25 mg/m2/day i.v. days 1 and 8; carboplatin 300 mg/m2/day i.v. day 1; ifosfamide 3 g/m2/day i.v. day I; and mesna 2.4 g/m2/day i.v. day 1 after completion of ifosfamide infusion, treatment repeated every 4 weeks). RESULTS: Among 26 patients, 23 patients were evaluable. Nine out of 23 evaluable patients had a partial response (response rate 39%; 95% confidence interval 19~59%). The median survival of the total 23 evaluable patients was 7.4 (range; 3~9.3+) months. The median progression-free survival was 2.8 (range; 0~7.7+) months. Among total 70 cycles of chemotherapy, leukopenia of grade II or more was observed in 6%, and tbrombo- cytopenia of grade II or more in 1%. There was no treatment-related death. Main non-hematologic toxicities were nausea/vomiting, stomatitis and peripheral phlebitis, almost of which were tolerable. CONCLUSION: NCI chemotherapy seemed to be moderately active and well tolerated in patients with advanced NSCLC.
